Develops dermatological and topical drug products, focusing on treatments for acne, rosacea, and other skin conditions.
Sol-Gel Technologies Ltd., a specialty pharmaceutical company in the clinical stage, specializes in the development and commercialization of innovative topical dermatological drug products utilizing its proprietary microencapsulation delivery system. Based in Israel, the company has established a robust pipeline that includes several lead product candidates. These include Twyneo, an advanced once-daily non-antibiotic topical cream which has successfully completed Phase III clinical trials targeting acne vulgaris. Additionally, Epsolay, another once-daily topical cream, has also completed Phase III trials aimed at treating papulopustular rosacea. Sol-Gel is further advancing SGT-210 through Phase I clinical trials, targeting palmoplantar keratoderma, alongside exploring the potential of Erlotinib, Tapinarof, and roflumilast for treating psoriasis and other medical conditions. The company is also actively engaged in developing generic topical dermatological drug products.
Sol-Gel Technologies Ltd. has forged strategic collaborations to enhance its capabilities and broaden its market reach. Notably, the company maintains a partnership with Perrigo, a collaboration aimed at leveraging joint expertise to advance dermatological therapies. Founded in 1997 and headquartered in Ness Ziona, Israel, Sol-Gel Technologies continues to drive innovation in dermatological treatments, combining cutting-edge science with a commitment to meeting unmet medical needs globally.
With a strong focus on research and development, Sol-Gel Technologies Ltd. remains dedicated to advancing its proprietary delivery system to improve the efficacy and safety profile of dermatological treatments. The company's comprehensive approach spans from early-stage clinical trials to commercialization, positioning it at the forefront of innovation in topical dermatology within the global pharmaceutical landscape.